Day: September 21, 2020

WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the closing of its initial public offering of 14,089,314 shares of its common stock at an initial public offering price of $19.00 per share, including 1,837,736 additional shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares in the offering were sold by Dyne. The gross proceeds of the offering, before deducting the underwriting discount and commissions and other offering expenses payable by Dyne, were approximately $268 million.The shares began trading on the Nasdaq Global Select Market on Thursday, September...

SUNNYVALE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced that it is strengthening its leadership team with two appointments. William Whealon, Ph.D. has joined the company as Executive Vice President of Research and Development, effective immediately. Silk Road Medical has also named Lucas Buchanan, the company’s current Chief Financial Officer, to also serve as its Chief Operating Officer, effective October 1, 2020.“We are excited to welcome Bill to Silk Road Medical as we further strengthen our leadership team. His proven track record for building and leading effective and innovative R&D groups and his passion for identifying solutions to solve unmet clinical needs will be instrumental in our continued...

Encouraging Efficacy Signals Observed in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer in the Phase Ib Study of NUC-3373 (NuTide:302)NUC-3373’s Favorable Pharmacokinetic and Safety Profile Unaffected by LeucovorinFirst-in-Human Data of NUC-7738 Shows Anti-Cancer Activity and a Favorable Tolerability ProfileEDINBURGH, United Kingdom, Sept. 21, 2020 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA), announced data from the ongoing NUC-3373 and NUC-7738 clinical programs, as well as a review of the ongoing Acelarin Phase III study, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress.NUC-3373 is NuCana’s targeted inhibitor of thymidylate synthase designed to overcome the main challenges associated with 5-FU including cancer resistance mechanisms, off-target toxicity and administration burdens. Data from...

SINGAPORE, Sept. 21, 2020 (GLOBE NEWSWIRE) — Grindrod Shipping Holdings Ltd. (NASDAQ: GRIN) (JSE: GSH) (“Grindrod Shipping” or “Company” or “it” or “we”), a global provider of maritime transportation services in the drybulk and product tanker sectors, announced two transactions with respect to its fleet.On September 15, 2020, the Company took delivery of the IVS Pebble Beach, a Japanese-built eco ultramax drybulk carrier newbuilding. As previously disclosed, the vessel has been chartered-in from its owner for a minimum period of two years with options to extend for up to two additional years, at Grindrod Shipping’s election. In addition, the Company holds options to purchase the vessel in the future.On September 2, 2020, the previously announced sale of the 2004-built handysize drybulk carrier IVS Nightjar was completed, with the...

IRVINE, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced that the interim results from the FLASH study have been accepted for presentation in a late-breaking clinical science session at TCT Connect. The FLASH study is evaluating the safety and effectiveness of the FlowTriever System for treatment of pulmonary embolism (PE) in a real-world patient population. Interim data on the first 230 patients enrolled at 19 US sites will be presented in the late-breaking session.“We are excited to feature the interim FLASH data as part of a late-breaking session at TCT Connect,” said Thomas Tu, MD, Chief Medical Officer of Inari Medical. “FLASH...

SARATOGA SPRINGS, N.Y., Sept. 21, 2020 (GLOBE NEWSWIRE) — Espey Mfg. & Electronics Corp. (NYSE American: ESP) announces results for its fourth quarter and fiscal year, ended June 30, 2020.For the fiscal year ended June 30, 2020, the Company reported net sales of $31,526,231 compared with $36,477,851 for the fiscal year ended June 30, 2019. Net income decreased to $1,163,668, $0.49 per diluted share for the year, compared with net income of $2,342,694, $0.98 per diluted share, for the fiscal year ended June 30, 2019. At June 30, 2020, the sales order backlog was $54.9 million, compared to last year’s backlog of $45.6 million at June 30, 2019.For the fourth quarter ended June 30, 2020, net sales increased to $12,124,438 compared with last year’s fourth quarter net sales of $11,619,202. The net income for the fourth quarter ended...

BIRMINGHAM, Ala., Sept. 21, 2020 (GLOBE NEWSWIRE) — ServisFirst Bancshares, Inc., (NASDAQ: SFBS) (“ServisFirst”), the holding company for ServisFirst Bank, today announces: At a meeting held on September 21, 2020, its Board of Directors declared a quarterly cash dividend of $0.175 per share, payable on October 9, 2020, to stockholders of record as of October 1, 2020.  About ServisFirst Bancshares, Inc.ServisFirst Bancshares, Inc. is a bank holding company based in Birmingham, Alabama. Through its subsidiary, ServisFirst Bank, ServisFirst Bancshares, Inc. provides business and personal financial services from locations in Birmingham, Huntsville, Mobile, Montgomery and Dothan, Alabama, Pensacola, Sarasota and Tampa Bay, Florida, Nashville, Tennessee, Atlanta, Georgia, and Charleston, South Carolina. ServisFirst Bancshares, Inc. files...

NEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) — Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced that it intends to offer and sell shares of its common stock and Series 1 convertible preferred stock in two concurrent but separate underwritten public offerings (together, the “Offerings”). The Offerings are subject to market and other conditions, and there can be no assurance as to whether or when the Offerings may be completed, or the actual size or terms of the Offerings.Cowen and Guggenheim Securities are acting as joint book-running managers. Oppenheimer & Co. is acting as lead manager for the Offerings, and H.C. Wainwright & Co. is acting as co-manager for the Offerings. Protara...

TEL AVIV, Israel, Sept. 21, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that Prof. Dror Harats, M.D., Chief Executive Officer, will provide a corporate overview, at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit being held virtually September 21-23, 2020.An archive recording will be available for listening after the event, on the Investor Relations page of VBL’s corporate website, under “Events & Presentations.”About VBLVascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer...

TAMPA, Fla., Sept. 21, 2020 (GLOBE NEWSWIRE) — Kforce Inc. (NASDAQ: KFRC) today provided an update to its expected third quarter results ahead of its scheduled presentation at the Sidoti 2020 Virtual Investor Conference on September 24, 2020. Based on its positive trends in the third quarter, Kforce now expects revenues and earnings per share to exceed the top end of its previously announced guidance of $362 million in revenues and earnings of $0.82 per share.David L Dunkel, Chief Executive Officer, commented, “Our results in the second quarter and expected results for the third quarter have demonstrated a remarkable level of resiliency, especially the performance of our technology business. We believe this is a testament to the strategic positioning of our Firm over the last several years to capitalize on the longer-term secular...